Oryzon Genomics SA ORYN:Mexico Stock Exchange

*Data is delayed | Exchange | MXN
Last | undefined
()
52 week range
0.00 - 0.00
Loading...
  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High0.00
  • 52 Week High Date-
  • 52 Week Low0.00
  • 52 Week Low Date-

Key Stats

  • Market Cap130.22M
  • Shares Out60.88M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High0.00
  • 52 Week High Date-
  • 52 Week Low0.00
  • 52 Week Low Date-
  • Market Cap130.22M
  • Shares Out60.88M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Oryzon Genomics SA

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in...
Carlos Manuel Buesa Arjol
Executive Chairman of the Board, Chief Executive Officer
Tamara Maes
First Vice Chairwoman, Proprietary Director
Enric Rello Condomines
Chief Financial Officer, Chief Operating Officer
Ana Limon Carrera
Senior Vice President - Clinical Development and Global Medical Affairs
Address
Sant Ferran 74
Cornella De Llobregat, BAR
08940
Spain